HNWAG
KYMR icon

High Net Worth Advisory Group’s Kymera Therapeutics KYMR Stock Holding History

High Net Worth Advisory Group’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-100
Closed -$6K – 703
2021
Q4 		$6K Buy
+100
New +$5.83K ﹤0.01% 584

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

High Net Worth Advisory Group's KYMR Position: Q1 2022 in Review

High Net Worth Advisory Group sold out of Kymera Therapeutics (KYMR) in Q1 2022, closing a stake of 100 shares — an estimated $6K sold.

High Net Worth Advisory Group first reported a position in KYMR in Q4 2021 and held it in 1 quarter. The position peaked at $6K in Q4 2021. 126 funds tracked by Wall St. Rank hold KYMR as of Q1 2022.

  • High Net Worth Advisory Group reported no remaining Kymera Therapeutics position as of Q1 2022 after selling out during the quarter.
  • High Net Worth Advisory Group sold 100 Kymera Therapeutics shares in Q1 2022, an estimated $6K.
  • High Net Worth Advisory Group first reported a position in Kymera Therapeutics in Q4 2021 and held it in 1 quarter.
  • High Net Worth Advisory Group's Kymera Therapeutics position peaked at $6K in Q4 2021.
  • 126 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q1 2022.

Based on High Net Worth Advisory Group's 13F filing for Q1 2022, filed 13 May 2022.